ArticleCJC pediatric and congenital heart disease2025
A Canadian Experience With a Percutaneous Microaxial Ventricular Assist Device in Children With Cardiogenic Shock.
Article in CJC pediatric and congenital heart disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The experience of a percutaneous microaxial (Impella) left ventricular assist device in children with cardiogenic shock is limited. The primary objective of this study was to review our institutional clinical outcomes of Impella use in children with cardiogenic shock. Methods: This is a single-center retrospective study of all adult-sized children who underwent Impella implantation from June 2019 to December 2024. Clinical outcomes, hemodynamics, and device complication data were collected. Results: A total of 7 patients (female = 4) with a median (interquartile range [IQR]) age of 15 years (14.5, 16.5 years) and a median weight of 50.9 kg (46.5, 59.85 kg) underwent Impella insertion during the study period. Five patients underwent Impella insertion for hemodynamic support and 2 for left ventricular decompression while on extracorporeal membrane oxygenation (ECMO) support. The underlying cardiac diagnoses were dilated cardiomyopathy (4 of 7), myocarditis (2 of 6), and hypertrophic cardiomyopathy with presumed myocarditis (1 of 7). The median (IQR) duration of support was 5 days (2, 7 days). The median (IQR) duration of intensive care unit and hospital stay was 13 days (10.5, 19 days) and 23 days (15, 54 days), respectively. Three patients were ultimately bridged to a durable ventricular assist device, and 2 patients had recovery of myocardial function. One patient developed significant aortic regurgitation, which necessitated device explantation and conversion to central ECMO after 38 hours of support, and one patient had withdrawal of life-sustaining measures due to significant brain injury unrelated to Impella. Conclusions: There is increasing use of percutaneous microaxial pumps for supporting children in cardiogenic shock and left ventricle decompression on ECMO support. This report identifies the initial Canadian experience as an addition to the mechanical circulatory support armamentarium.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.